HCW Biologics Inc. (HCWB) financial statements (2022 and earlier)

Company profile

Business Address 2929 N COMMERCE PKWY
MIRAMAR, FL 33025
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments36,71440,1155,051
Cash and cash equivalents11,73115,1255,051
Short-term investments24,98424,990 
Receivables1337050
Prepaid expense2,1971,991862
Deferred costs  3,189
Other current assets1,4371,383894
Total current assets:40,48043,55910,046
Noncurrent Assets
Property, plant and equipment1,1191,2691,387
Long-term investments and receivables11,52211,5781,600
Long-term investments11,52211,5781,600
Other noncurrent assets393  
Total noncurrent assets:13,03412,8472,987
TOTAL ASSETS:53,51556,40613,033
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,1001,8003,200
Accounts payable224637997
Other undisclosed accounts payable and accrued liabilities1,8761,1632,203
Other undisclosed current liabilities222595969
Total current liabilities:2,3222,3954,169
Noncurrent Liabilities
Total liabilities:2,3222,3954,169
Temporary equity, carrying amount  32,104
Stockholders' equity
Stockholders' equity attributable to parent, including:51,19354,011(23,240)
Additional paid in capital81,82781,472 
Accumulated deficit(30,637)(27,464)(23,240)
Other undisclosed stockholders' equity attributable to parent440
Total stockholders' equity:51,19354,011(23,240)
TOTAL LIABILITIES AND EQUITY:53,51556,40613,033

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
Operating expenses(3,113)(4,092)(2,751)
Operating loss:(3,113)(4,092)(2,751)
Loss from continuing operations before equity method investments, income taxes:(3,113)(4,092)(2,751)
Other undisclosed loss from continuing operations before income taxes(62)  
Net loss:(3,174)(4,092)(2,751)
Other undisclosed net income (loss) attributable to parent1(3)1
Net loss attributable to parent:(3,173)(4,095)(2,750)
Preferred stock dividends and other adjustments  (483)
Net loss available to common stockholders, diluted:(3,173)(4,095)(3,233)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
Net loss:(3,174)(4,092)(2,751)
Comprehensive loss, net of tax, attributable to parent:(3,174)(4,092)(2,751)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: